Jentashapir Journal of Health Research

Published by: Kowsar

Pharmacotherapy Updates of Recombinant Tissue Plasminogen Activator (r-TPA) in Acute Ischemic Stroke

Zahra Tolou Ghamari 1 , * and Hamid Mazdak 1
Authors Information
1 Isfahan Kidney Transplantation Research Center, Alzahra Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Jentashapir Journal of Health Research: June 2016, 7 (3); e36067
  • Published Online: April 26, 2016
  • Article Type: Review Article
  • Received: January 5, 2016
  • Accepted: March 28, 2016
  • DOI: 10.17795/jjhr-36067

To Cite: Tolou Ghamari Z, Mazdak H. Pharmacotherapy Updates of Recombinant Tissue Plasminogen Activator (r-TPA) in Acute Ischemic Stroke, Jundishapur J Helath Res. 2016 ;7(3):e36067. doi: 10.17795/jjhr-36067.

Abstract
Copyright: Copyright © 2016, Jentashapir Journal of Health Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
References
  • 1. Weaver J, Liu KJ. Does normobaric hyperoxia increase oxidative stress in acute ischemic stroke? A critical review of the literature. Med Gas Res. 2015; 5: 11[DOI][PubMed]
  • 2. Michalski D, Küppers-Tiedt L, Weise C, Laignel F, Härtig W, Raviolo M, et al. Long-term functional and neurological outcome after simultaneous treatment with tissue-plasminogen activator and hyperbaric oxygen in early phase of embolic stroke in rats. Brain Res. 2009; 1303: 161-8[DOI]
  • 3. O’Carroll CB, Aguilar MI. Management of postthrombolysis hemorrhagic and orolingual angioedema complications. Neurohospitalist. 2015; 5(3): 133–41[DOI]
  • 4. Paramasivam S. Current trends in the management of acute ischemic stroke. Neurol India. 2015; 63(5): 665-72[DOI]
  • 5. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology. 2013; 80(1): 21-8[DOI][PubMed]
  • 6. Kirkman MA, Lambden S, Smith M. Challenges in the Anesthetic and Intensive Care Management of Acute Ischemic Stroke. J Neurosurg Anesthesiol. 2015; [DOI][PubMed]
  • 7. Shi L, Xu L, Shi L, Brandon D, Chen S, Zhang J. Intraventricular Recombinant Tissue Plasminogen Activator in Treatment of Aneurysmal Intraventricular Hemorrhage: A Meta-Analysis. Curr Drug Targets. 2015; [PubMed]
  • 8. Twomey JA, Peltier GL, Zera RT. An open-label study to evaluate the safety and efficacy of tissue plasminogen activator in treatment of severe frostbite. J Trauma. 2005; 59(6): 1350-4[PubMed]
  • 9. Newman DH, Shreves AE. Thrombolysis in acute ischaemic stroke. Lancet. 2012; 380(9847): 1053-4[DOI][PubMed]
  • 10. Dornak T, Kral M, Hazlinger M, Herzig R, Veverka T, Burval S, et al. Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis. Int J Stroke. 2015; 10(8): 1224-8[DOI]
  • 11. Sorkin GC, Dumont TM, Mokin M, Eller JL, Natarajan SK, Levy EI, et al. Hyperacute carotid stent thrombosis during emergent revascularization treated with intraarterial eptifibatide after systemic administration of recombinant tissue plasminogen activator. J Vasc Interv Neurol. 2015; 8(3): 50-5
  • 12. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012; 379(9834): 2364-72[DOI][PubMed]
  • 13. Shirakawa M, Yoshimura S, Yamada K, Uchida K, Shindou S. Endovascular Treatment for Acute Ischemic Stroke: Considerations from Recent Randomized Trials. Interv Neurol. 2015; 3(3-4): 115-21[DOI][PubMed]
  • 14. Sugiyama T, Kazumata K, Asaoka K, Osanai T, Shimbo D, Uchida K, et al. Reappraisal of Microsurgical Revascularization for Anterior Circulation Ischemia in Patients with Progressive Stroke. World Neurosurg. 2015; 84(6): 1579-88[DOI]
  • 15. Bankhead C, Agus ZS. Clot-busting drugs used more often in stroke. 2013;
  • 16. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals. Circ Cardiovasc Qual Outcomes. 2013; [DOI][PubMed]
  • 17. Mateen FJ, Nasser M, Spencer BR, Freeman WD, Shuaib A, Demaerschalk BM, et al. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older. Mayo Clin Proc. 2009; 84(4): 334-8[DOI][PubMed]
  • 18. Adams HJ. IV thrombolysis for treatment of patients with stroke upon awakening: Yes? No? Neurol Clin Pract. 2015; 5(4): 296-301[DOI][PubMed]
  • 19. Spokoyny I, Raman R, Ernstrom K, Kim AJ, Meyer BC, Karanjia NP. Accuracy of First Recorded "Last Known Normal" Times of Stroke Code Patients. J Stroke Cerebrovasc Dis. 2015; 24(11): 2467-73[DOI][PubMed]
  • 20. Horsch AD, Dankbaar JW, van der Graaf Y, Niesten JM, van Seeters T, van der Schaaf IC, et al. Relation between reperfusion and hemorrhagic transformation in acute ischemic stroke. Neuroradiology. 2015; 57(12): 1219-25[DOI][PubMed]
  • 21. Tsurupa G, Medved L. Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains. Biochemistry. 2001; 40(3): 801-8[PubMed]
  • 22. Orth K, Madison EL, Gething MJ, Sambrook JF, Herz J. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Proc Natl Acad Sci U S A. 1992; 89(16): 7422-6[PubMed]
  • 23. Parmar PK, Coates LC, Pearson JF, Hill RM, Birch NP. Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J Neurochem. 2002; 82(6): 1406-15[PubMed]
  • 24. Brimelow A. Safety review into stroke clot-buster drug alteplase. BBC News. 2015;
  • 25. Saqqur M, Shuaib A, Alexandrov AV, Sebastian J, Khan K, Uchino K. The correlation between admission blood glucose and intravenous rt‐PA‐induced arterial recanalization in acute ischemic stroke: a multi‐centre TCD study. Int J Stroke. 2015; 10(7): 1087-92[DOI]
  • 26. Gong L, Liu M, Zeng T, Shi X, Yuan C, Andreasen PA, et al. Crystal structure of the Michaelis complex between tissue-type plasminogen activator and plasminogen activators inhibitor-1. J Biolog Chem. 2015; 290(43): 25795-804
  • 27. Fugate JE, Rabinstein AA. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. Neurohospitalist. 2015; 5(3): 110-21[DOI][PubMed]
  • 28. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009; 40(7): 2442-9[DOI][PubMed]
  • 29. Tolou-Ghamari Z, Mortazavi M, Palizban AA, Najafi MR. The investigation of correlation between Iminoral concentration and neurotoxic levels after kidney transplantation. Adv Biomed Res. 2015; 4[DOI]
  • 30. Tolou-Ghamari Z, Zare M, Habibabadi JM, Najafi MR. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. J Res Med Sci. 2013; 18-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .